Peter A Kavsak1, Joshua O Cerasuolo2, Dennis T Ko2, Jinhui Ma2, Jonathan Sherbino2, Shawn E Mondoux2, Natasha Clayton2, Stephen A Hill2, Matthew McQueen2, Lauren E Griffith2, Shamir R Mehta2, Richard Perez2, Hsien Seow2, P J Devereaux2, Andrew Worster2. 1. Department of Pathology and Molecular Medicine (Kavsak, Hill, McQueen), McMaster University; ICES McMaster (Cerasuolo, Perez, Seow), Faculty of Health Sciences, McMaster University, Hamilton, Ont.; ICES (Ko), Toronto, Ont.; Department of Health Research Methods, Evidence, and Impact (Ma, Griffith); Division of Emergency Medicine (Sherbino, Mondoux, Worster); Department of Medicine (Clayton); Division of Cardiology, and Population Health Research Institute (Mehta, Devereaux), McMaster University, Hamilton, Ont. kavsakp@mcmaster.ca. 2. Department of Pathology and Molecular Medicine (Kavsak, Hill, McQueen), McMaster University; ICES McMaster (Cerasuolo, Perez, Seow), Faculty of Health Sciences, McMaster University, Hamilton, Ont.; ICES (Ko), Toronto, Ont.; Department of Health Research Methods, Evidence, and Impact (Ma, Griffith); Division of Emergency Medicine (Sherbino, Mondoux, Worster); Department of Medicine (Clayton); Division of Cardiology, and Population Health Research Institute (Mehta, Devereaux), McMaster University, Hamilton, Ont.
Abstract
BACKGROUND: The ability to rule out or in a major adverse cardiac event (MACE) in patients with suspected acute coronary syndrome at emergency department (ED) presentation would be beneficial to patient care and the health care system. The clinical chemistry score (CCS) was evaluated in this context. METHODS: This diagnostic accuracy study evaluated 2 different ED cohorts with suspected acute coronary syndrome. For patients in cohort 1, who presented to the ED of 3 hospitals in Hamilton, Ontario, between May and August 2013, retrospective measurements were taken using the Ortho Clinical Diagnostics high-sensitivity cardiac troponin I (hs-cTnI) assay; for patients in cohort 2, who presented to the ED of the same 3 hospitals in Hamilton between November 2012 and February 2013, an ED cardiac presentation blood test panel was performed with the Abbott Diagnostics hs-cTnI assay. The sensitivity and specificity of the CCS (cut-offs of ≥ 1 and 5) and hs-cTnI alone (published cut-offs) were compared for MACE (composite of death, myocardial infarction, unstable angina, revascularization) at 30 days for both cohorts and at 90 days for cohort 2. RESULTS: The incidence of MACE at 30 days was higher in cohort 1 (n = 1058) (19.4%, 95% confidence interval [CI] 16.8%-22.2%) than in cohort 2 (n = 5974) (14.6%, 95% CI 13.6%-15.6%). In cohort 1, a CCS of 1 or above yielded a sensitivity of 99.5% (95% CI 97.3%-99.9%). The sensitivity with an Ortho hs-cTnI cut-off of 1 ng/L or above was 91.2% (95% CI 86.5%-95.7%). The specificity of a CCS of 5 (97.8%, 95% CI 96.5%-98.7%) was higher than when the overall 99th-percentile cut-off for the Ortho hs-cTnI assay (> 11 ng/L; 90.1%, 95% CI 87.9%-92.0%) was used. A similar pattern was observed in cohort 2 at 30 days and persisted at 90 days with the Abbott hs-cTnI assay. INTERPRETATION: The CCS derived with 2 different hs-cTnI assays and ED populations yielded higher sensitivity and specificity estimates for MACE than hs-cTnI alone. An intervention study is needed to evaluate the impact of the CCS at both the patient and hospital levels. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01994577. Copyright 2020, Joule Inc. or its licensors.
BACKGROUND: The ability to rule out or in a major adverse cardiac event (MACE) in patients with suspected acute coronary syndrome at emergency department (ED) presentation would be beneficial to patient care and the health care system. The clinical chemistry score (CCS) was evaluated in this context. METHODS: This diagnostic accuracy study evaluated 2 different ED cohorts with suspected acute coronary syndrome. For patients in cohort 1, who presented to the ED of 3 hospitals in Hamilton, Ontario, between May and August 2013, retrospective measurements were taken using the Ortho Clinical Diagnostics high-sensitivity cardiac troponin I (hs-cTnI) assay; for patients in cohort 2, who presented to the ED of the same 3 hospitals in Hamilton between November 2012 and February 2013, an ED cardiac presentation blood test panel was performed with the Abbott Diagnostics hs-cTnI assay. The sensitivity and specificity of the CCS (cut-offs of ≥ 1 and 5) and hs-cTnI alone (published cut-offs) were compared for MACE (composite of death, myocardial infarction, unstable angina, revascularization) at 30 days for both cohorts and at 90 days for cohort 2. RESULTS: The incidence of MACE at 30 days was higher in cohort 1 (n = 1058) (19.4%, 95% confidence interval [CI] 16.8%-22.2%) than in cohort 2 (n = 5974) (14.6%, 95% CI 13.6%-15.6%). In cohort 1, a CCS of 1 or above yielded a sensitivity of 99.5% (95% CI 97.3%-99.9%). The sensitivity with an Ortho hs-cTnI cut-off of 1 ng/L or above was 91.2% (95% CI 86.5%-95.7%). The specificity of a CCS of 5 (97.8%, 95% CI 96.5%-98.7%) was higher than when the overall 99th-percentile cut-off for the Ortho hs-cTnI assay (> 11 ng/L; 90.1%, 95% CI 87.9%-92.0%) was used. A similar pattern was observed in cohort 2 at 30 days and persisted at 90 days with the Abbott hs-cTnI assay. INTERPRETATION: The CCS derived with 2 different hs-cTnI assays and ED populations yielded higher sensitivity and specificity estimates for MACE than hs-cTnI alone. An intervention study is needed to evaluate the impact of the CCS at both the patient and hospital levels. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01994577. Copyright 2020, Joule Inc. or its licensors.
Authors: Colleen Shortt; Jinhui Ma; Natasha Clayton; Jonathan Sherbino; Richard Whitlock; Guillaume Pare; Stephen A Hill; Matthew McQueen; Shamir R Mehta; P J Devereaux; Andrew Worster; Peter A Kavsak Journal: Clin Chem Date: 2016-11-10 Impact factor: 8.327
Authors: W Frank Peacock; Brigette M Baumann; Deborah Bruton; Thomas E Davis; Beverly Handy; Christopher W Jones; Judd E Hollander; Alexander T Limkakeng; Abhi Mehrotra; Martin Than; Andre Ziegler; Carina Dinkel Journal: JAMA Cardiol Date: 2018-02-01 Impact factor: 14.676
Authors: Peter A Kavsak; Shawn E Mondoux; Jonathan Sherbino; Jinhui Ma; Natasha Clayton; Stephen A Hill; Matthew McQueen; Shamir R Mehta; Lauren E Griffith; P J Devereaux; Andrew Worster Journal: Clin Biochem Date: 2020-04-15 Impact factor: 3.281
Authors: Christian A Tomaszewski; David Nestler; Kaushal H Shah; Amita Sudhir; Michael D Brown Journal: Ann Emerg Med Date: 2018-11 Impact factor: 5.721
Authors: Geoffrey Lau; Maria Koh; Peter A Kavsak; Michael J Schull; David W J Armstrong; Jacob A Udell; Peter C Austin; Xuesong Wang; Dennis T Ko Journal: Am Heart J Date: 2019-12-11 Impact factor: 4.749
Authors: Peter A Kavsak; Shawn E Mondoux; Janet Martin; Mark K Hewitt; Lorna Clark; Nadia Caruso; Ching-Tong Mark; V Tony Chetty; Craig Ainsworth; Andrew Worster Journal: J Cardiovasc Dev Dis Date: 2021-03-23